- Trials with a EudraCT protocol (66)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
66 result(s) found for: Sarcomatoid Carcinoma.
Displaying page 1 of 4.
EudraCT Number: 2007-005090-65 | Sponsor Protocol Number: VALPAX | Start Date*: 2007-10-18 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: New therapeutic approaches in the treatment of anaplastic thyroid cancer: a phase II trial of valproic acid and paclitaxel in solid tumours | |||||||||||||
Medical condition: Patients with anaplastic thyroid cancer or with metastatic solid tumours | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005221-11 | Sponsor Protocol Number: MUTAVA | Start Date*: 2008-10-22 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: New therapeutic approaches for anaplastic thyroid cancer: assessment of the benefit-risk profile of the combination valproic acid-paclitaxel. | |||||||||||||
Medical condition: Patients with undifferentiated thyroid cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004351-75 | Sponsor Protocol Number: MK-3475-564 | Start Date*: 2017-05-31 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) | |||||||||||||
Medical condition: Treatment of participants with RCC in the adjuvant setting | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) FI (Trial now transitioned) DE (Trial now transitioned) GB (Completed) PL (Trial now transitioned) ES (Ongoing) FR (Ongoing) IE (Trial now transitioned) NL (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000502-29 | Sponsor Protocol Number: WO41994 | Start Date*: 2020-09-01 | |||||||||||||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERAB... | |||||||||||||||||||||||
Medical condition: Renal cell carcinoma (RCC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) FR (Prematurely Ended) IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002941-12 | Sponsor Protocol Number: INCMGA0012-203 | Start Date*: 2019-06-19 | ||||||||||||||||||||||||||
Sponsor Name:Incyte Corporation | ||||||||||||||||||||||||||||
Full Title: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203) | ||||||||||||||||||||||||||||
Medical condition: Male or female, 18 years or older with histologically or cytologically confirmed diagnosis of : a. NSCLC with high PD-L1 expression (TPS ≥ 50%) and no EGFR, ALK, or ROS activating genomic tumor ab... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: AT (Completed) HU (Completed) PL (Completed) ES (Ongoing) IT (Ongoing) RO (Ongoing) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-012714-49 | Sponsor Protocol Number: CHUBX 2009/04 | Start Date*: 2009-11-24 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Pilot study of Lapatinib (Tyverb®) in néoadjuvant treatment for patients with locally bladder carcinoma before cystectomy | |||||||||||||
Medical condition: Bladder carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012010-52 | Sponsor Protocol Number: mRCC | Start Date*: 2009-08-04 | |||||||||||
Sponsor Name:Department of Oncology, Aarhus University Hospital | |||||||||||||
Full Title: Bevacizumab, Interleukin-2 and Interferon-alpha in metastathic renal cell carcinoma | |||||||||||||
Medical condition: Patient with previously untreated Metastatic Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004570-34 | Sponsor Protocol Number: 01045-ATLEP | Start Date*: 2018-11-15 | ||||||||||||||||
Sponsor Name:Medical Center - University of Freiburg | ||||||||||||||||||
Full Title: Phase II, Open-label, Study in Patients with anaplastic (ATC) or poorly differentiated thyroid carcinomas (PDTC) to investigate the Clinical Efficacy and Safety of the Combination Therapy of Lenvat... | ||||||||||||||||||
Medical condition: Anaplastic (ATC) or Poorly Differentiated Thyroid Carcinoma (PDTC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002846-38 | Sponsor Protocol Number: OXC4T4-302 | Start Date*: 2007-12-06 | |||||||||||
Sponsor Name:OXiGENE, Inc. | |||||||||||||
Full Title: A multicenter, open-label, randomized, phase II/III study to evaluate the safety and efficacy of combretastatin a-4 phosphate in combination with paclitaxel and carboplatin in comparison with pacli... | |||||||||||||
Medical condition: Anaplastic Thyroid Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) IT (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001032-12 | Sponsor Protocol Number: PANTHERA | Start Date*: 2008-10-28 | |||||||||||||||||||||
Sponsor Name:Universitätsklinikum Schleswig-Holstein | |||||||||||||||||||||||
Full Title: Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer | |||||||||||||||||||||||
Medical condition: recurrent/advanced follicular, papillary or anaplastic thyroid cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prohibited by CA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001316-38 | Sponsor Protocol Number: UR1909 | Start Date*: 2019-11-20 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Department of Oncology, Herlev University Hospital | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma | ||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004223-16 | Sponsor Protocol Number: PEBBLE | Start Date*: 2021-05-10 | |||||||||||
Sponsor Name:Queen Mary University of London | |||||||||||||
Full Title: A phase II study investigating preoperative bintrafusp alfa in operable urothelial carcinoma of the bladder. | |||||||||||||
Medical condition: Urothelial carcinoma requiring radical cystectomy with bilateral pelvic lymph node dissection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013219-37 | Sponsor Protocol Number: AV-951-09-301 | Start Date*: 2010-02-02 | ||||||||||||||||
Sponsor Name:AVEO Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma | ||||||||||||||||||
Medical condition: Advanced Renal Cell Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Ongoing) FR (Ongoing) PL (Completed) CZ (Completed) IT (Ongoing) BG (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-003793-26 | Sponsor Protocol Number: 3066K1-3311-WW | Start Date*: 2008-05-19 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | |||||||||||||
Full Title: Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma | |||||||||||||
Medical condition: First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) FR (Completed) BE (Completed) PT (Completed) CZ (Completed) DE (Completed) SK (Completed) NL (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001066-42 | Sponsor Protocol Number: GETNE-T1812 | Start Date*: 2020-02-20 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Spanish Group of Neuroendocrine Tumors (GETNE) | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma - The DUTHY trial | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC). Advanced medullary thyroid carcino... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001454-18 | Sponsor Protocol Number: UG1617 | Start Date*: 2016-10-05 | |||||||||||
Sponsor Name:Center for Cancer Immune Therapy | |||||||||||||
Full Title: T cell therapy for patients with advanced Renal Cell Carcinoma | |||||||||||||
Medical condition: Advanced Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004945-40 | Sponsor Protocol Number: GEN204 | Start Date*: 2007-03-29 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Can... | |||||||||||||
Medical condition: Stage IIIA-IIIB Non Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) BE (Completed) DE (Completed) NL (Prematurely Ended) FR (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004695-35 | Sponsor Protocol Number: CA209-8Y8 | Start Date*: 2019-06-10 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- ... | |||||||||||||
Medical condition: Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) CZ (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) PT (Completed) GR (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000107-28 | Sponsor Protocol Number: 11726 | Start Date*: 2008-04-15 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC) | |||||||||||||
Medical condition: Renal Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001907-18 | Sponsor Protocol Number: MK-6482 | Start Date*: 2020-09-14 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
Full Title: Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | ||||||||||||||||||
Medical condition: Advanced Renal Cell Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) GR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.